The presented work consists on the research-development of a new product, by chemical synthesis, with simultaneous bactericide-fungicide action, from which it is not known the existence of a similar product in the market. This fact by itself gives a high scientific novelty to this work, which on the other hand represents an intangible value that has been appropriately protected, endorsed by the concession of 4 patents (1 in Cuba, 1 in Canada and 2 in Japan). The compound's structure has been demonstrated in a reliable way and subjected to scientific critic (Zeitschrift fur Kristallographie, Acta Crystallographica, Journal of molecular Structure), as well as the analytic techniques for the quality control of its production (Affinity).

The demonstration of its action, without being able so far to describe the action manner which explains such a simultaneous effect, has been made through an extensive research work live and in vitro, which has been subjected to a rigorous scientific criticism in very important magazines of the specialty, such as International Journal of Antimicrobial Agents, Journal of Veterinary Pharmacology & Therapy and Mutation Research. Also, it has the Certificate of Registration as Medicament for veterinary use in keratitis (No. 211 / 93).

And last but not least, there are 3 Reports of Studies carried out in prestigious institutions of North America that endorse the pharmaco-toxicological effects of G-1, such as Pharmadem (Canada) and Sitek Research Laboratories (USA).